Innovative antibody-based cancer therapeutics
MacroGenics (macrogenics.com) scores 74 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 42nd percentile of 19793 Healthcare brands.
MacroGenics is a clinical-stage biopharmaceutical company headquartered in Rockville, United States, founded in 2000. It develops next-generation antibody-based therapies-including antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers-primarily for cancer, with additional focus on hematology and autoimmune diseases. The company uses proprietary platform technologies and partners with global biopharmaceutical companies to advance its pipeline, having achieved FDA-approved therapies through these collaborations.
| Brand Name | MacroGenics |
|---|---|
| Domain | macrogenics.com |
| Industry | Healthcare |
| Founded | 2000 |
| Headquarters | Rockville |
| Main Competitors | Genmab (83/100), Zymeworks, Xencor (75/100), Seagen (84/100), Regeneron (92/100), Mersana Therapeutics (78/100), ImmunoGen (66/100), Amgen (90/100) |
Moz Domain Authority 40/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,088,235 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "To improve the lives of cancer patients by developing next-generation antibody-based therapies." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, X (Twitter), Instagram, GitHub; no detected presence on Facebook, YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is MacroGenics?", Claude could identify the brand as of October 2026. MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer treatment, using its proprietary technology platforms like DART (Dual-Affinity Re-Targeting) to create bispecific antibodies that engage the immu Best known for its DART platform for creating bispecific antibodies and its drug Margenza (margetuximab) for HER2-positive breast cancer.
When asked "Best brands similar to MacroGenics?", Claude would recommend MacroGenics as of October 2026. It's a recognized player in oncology biotech with a notable proprietary antibody platform, making it relevant when discussing immuno-oncology or bispecific antibody companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
MacroGenics's main competitors in Healthcare: Genmab (83/100), Xencor (75/100), Seagen (84/100), Regeneron (92/100), Mersana Therapeutics (78/100).
Sources: Brand Analyzer scan
MacroGenics offers a pipeline of antibody-based therapeutics developed through its proprietary platforms, including antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers. These are designed primarily to treat cancer, with some application toward hematology and autoimmune diseases, often advanced in partnership with other biopharmaceutical companies.
Sources: MacroGenics official site
MacroGenics is a clinical-stage biopharmaceutical company based in Rockville, United States, founded in 2000. It focuses on developing next-generation antibody-based therapies to treat cancer, with additional work in hematology and autoimmune diseases.
Sources: MacroGenics official site
MacroGenics has limited AI-search visibility, scoring 31/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 26, recommendation 53). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: MacroGenics official site
MacroGenics was founded in 2000. MacroGenics operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
MacroGenics is headquartered in Rockville. MacroGenics operates in the Healthcare category.
Sources: Wikidata
MacroGenics develops antibody-based therapeutics using proprietary platform technologies such as antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers. It advances a pipeline of novel cancer treatments, often in collaboration with global biopharmaceutical partners, and has contributed to FDA-approved therapies through these partnerships.
Sources: MacroGenics official site
MacroGenics scores 53/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: MacroGenics official site
MacroGenics is known for its proprietary antibody platform technologies-including antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers-and for its track record of achieving FDA-approved therapies through strategic biopharmaceutical partnerships.
Sources: MacroGenics official site
MacroGenics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: MacroGenics official site
MacroGenics' therapies are intended for cancer, hematology, and autoimmune disease patients. The company also works closely with biopharmaceutical partners and the broader medical and scientific community to develop and commercialize its antibody-based treatments.
Sources: MacroGenics official site
MacroGenics scores 31/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
MacroGenics has a weak AI-visibility profile at 31/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (53/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #1,088,235 (Tranco) and a Moz Domain Authority of 40/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify MacroGenics from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to MacroGenics: Sint Maartenskliniek (74/100), Lyssn (74/100), Magellan Healthcare (74/100), MagView (74/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.